Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03930680 · ClinicalTrials.gov registry record · Phase 1
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
A Phase 1 study of Degradation of Top2b and Top2a in Human by Dexrazoxane and Time Course and Degradation of Top2b in Human by Dexrazoxane, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT03930680: Completed Phase 1 study of Degradation of Top2b and Top2a in Human by Dexrazoxane and Time Course and Degradation of Top2b in Human by Dexrazoxane, sponsored by University of Arkansas.
NCT03930680 is a Phase 1 study of Degradation of Top2b and Top2a in Human by Dexrazoxane and Time Course and Degradation of Top2b in Human by Dexrazoxane that has completed, run by University of Arkansas. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03930680, a Phase 1 study of Degradation of Top2b and Top2a in Human by Dexrazoxane and Time Course and Degradation of Top2b in Human by Dexrazoxane, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.
Primary Outcome
Number of participants with 95% reduction in topoisomerase 2 b from baseline is reported in the Outcome Measure Data Table
Conditions Studied
Interventions
- DRUG Dexrazoxane
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2025-06-11 |
| Phase | Phase 1 |
What the finished NCT03930680 record still lists
NCT03930680 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 3 conditions, with Degradation of Top2b and Top2a in Human by Dexrazoxane appearing as the primary indexed condition, and to 1 intervention - of which Dexrazoxane is the first listed.
NCT03930680 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT03930680 about?
NCT03930680 is a clinical study titled "Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane". The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.
What is the current status of trial NCT03930680?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2021-09-14. Estimated completion is 2025-06-11.
What conditions does trial NCT03930680 study?
This clinical trial studies the following conditions: Degradation of Top2b and Top2a in Human by Dexrazoxane, Time Course and Degradation of Top2b in Human by Dexrazoxane, Effects of Dexrazoxane on Healthy Human.
What interventions are being tested in trial NCT03930680?
The interventions under investigation include: Dexrazoxane (DRUG).
Who is sponsoring clinical trial NCT03930680?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03930680 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03930680's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI